Retatrutide — triple agonist from incretin research
Research compound for studies on incretin signaling, receptor pharmacology, and energy metabolism. As Vial (lyophilized) or Pen.
Retatrutide simultaneously activates three metabolically relevant hormone receptors — a unique profile for basic research on energy homeostasis and incretin signaling.
GLP-1R signaling is investigated in the context of insulin secretion and gastric motility; the receptor pharmacology is extensively documented in the literature.
GIPR signaling is investigated in the context of insulin secretion and in adipocyte models (Finan et al., Sci Transl Med 2013).
In addition to GLP-1R and GIPR, retatrutide addresses a further class B receptor, which is studied mainly in hepatic models of energy expenditure (Coskun et al., Cell Metab 2022).
In preclinical models, lipid metabolism-related signalling cascades are studied under combined multi-receptor activation.
As Vial or Pen. Analysis reports shown per product. Shipping to 25 EU countries, 24–48 h after receipt of payment.
Selected peer-reviewed publications on which research in this area is based.
2023 · N Engl J Med
Phase 2 trial of the triple agonist Retatrutide (LY3437943)
2013 · Sci Transl Med
Unimolecular dual incretin agonists (preclinical study)
2018 · Diabetes Obes Metab
Incretin hormones: Their role in health and disease
In-depth articles on compounds and mechanisms in this research area.
Retatrutide activates three related hormone receptors, including the GLP-1 and GIP receptors. Receptor pharmacology, comparison with tirzepatide, the TRIUMPH trial programme, safety data and approval status – with sources.
Read more → JournalPeptides explained simply: amino acids, the peptide bond, how peptides differ from proteins, synthesis via SPPS, analysis with HPLC and MS, and the difference between cosmetic and…
Read more →All products on SunPept are intended exclusively for scientific research and laboratory purposes (Research Use Only). They are not for human or veterinary use, not for consumption, and not intended for therapeutic purposes.
I do not agree